Veru Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended March 31, 2020. The filing was signed May 13, 2020. Veru sells FC2 and PREBOOST and is developing drug candidates in oncology and urology.
Financial performance and liquidity
| Metric | Three months ended March 31, 2020 | Prior-year quarter | Six months ended March 31, 2020 | Prior-year six months |
|---|---|---|---|---|
| Net revenue | $9.94 million | $6.98 million | $20.52 million | $13.35 million |
| Gross profit / margin | $7.44 million / 75% | $4.61 million / 66% | $14.71 million / 72% | $9.25 million / 69% |
| Operating loss | $0.30 million | $2.12 million | $2.08 million | $3.14 million |
| Net loss | $0.81 million | $4.03 million | $4.12 million | $6.18 million |
| Net loss per share, basic and diluted | $0.01 | $0.06 | $0.06 | $0.10 |
- Revenue growth reflected higher FC2 sales in the U.S. prescription channel, partly offset by lower global public-sector sales. FC2 generated 96% of quarterly revenue and 97% for the six-month period.
- Quarterly FC2 revenue rose 39% despite unit sales falling 30%; average selling price per unit increased 98%. For six months, FC2 revenue rose 51%, unit sales declined 1%, and average price rose 53%. PREBOOST revenue was $421,000 for the quarter and $574,000 for six months.
- Research and development expense increased to $3.93 million for the quarter and $9.23 million for six months, reflecting development-program and personnel costs. Six-month selling, general and administrative expense was $7.56 million, versus $7.12 million a year earlier.
- Operating cash use was $4.93 million for six months, versus $4.00 million. Investing cash use was $55,000; financing provided $1.24 million. Cash declined by $3.74 million, from $6.30 million at September 30, 2019 to $2.56 million.
- At March 31, 2020, working capital was approximately $0.64 million, total assets $55.88 million, total liabilities $24.76 million, and stockholders’ equity $31.11 million. Management attributed lower working capital partly to increased current debt and newly recognized lease liabilities.
- SWK credit-agreement carrying value was $9.00 million, including $6.66 million current; the filing estimated about $6.7 million of revenue-based payments due in the following 12 months. The agreement’s aggregate repayment obligation is $17.65 million before cumulative payments and other accounting adjustments. The residual royalty agreement liability was $4.41 million. These arrangements are tied to FC2 revenue.
Changes, outlook and material risks
- Management said cash, expected commercial-product sales, and potential financing sources were adequate for planned operations for the next 12 months. The company has continued operating losses and expects substantial cash use and losses as it develops drug candidates; additional financing may be needed.
- Management warned that its largest U.S. telemedicine customer might reduce orders in fiscal Q3, potentially lowering revenue and gross margin. Public-sector orders are uneven and subject to tender timing, pricing pressure, and government purchasing decisions; three customers accounted for 80% of quarterly revenue.
- COVID-19 temporarily halted FC2 manufacturing and shipment at the sole Malaysian facility beginning March 16. The facility received permission to ship existing inventory from March 27, resumed manufacturing at reduced staffing on April 20, and returned to full staffing on May 4, with distancing measures. The company reported sufficient inventory at the time but flagged possible raw-material, labor, shipping, demand, and customer-payment disruptions.
- COVID-19 created clinical-trial enrollment, site-access, imaging, and regulatory risks. Veru postponed the first Phase 3 zuclomiphene trial until at least late 2020 or greater clarity on the pandemic. The prostate-cancer VERU-111 Phase 2 trial was continuing to enroll, subject to disruption risk.
- Veru reported FDA permission to start a 40-patient, randomized Phase 2 trial of VERU-111 for COVID-19. BARDA and DARPA funding applications were pending, with no assurance of grant support. The candidate’s COVID-19 use was early-stage and its efficacy was uncertain.
- Other stated development plans included discussions with FDA on a potential VERU-111 prostate-cancer Phase 3 design, a potential late-2020 Phase 3 start for zuclomiphene citrate, a potential third-quarter 2020 VERU-100 Phase 2 start, and a TADFIN NDA submission targeted for late 2020 or early 2021. Timing could change.
- In April 2020, after quarter-end, Veru received approximately $540,000 under the Paycheck Protection Program. Forgiveness depends on meeting program conditions; the filing discusses eligibility, repayment, and reputational risks.
- The filing reported no material pending legal proceedings, no material changes to previously disclosed risk factors apart from COVID-19-related additions, and effective disclosure controls.
Important facts for investors to verify
- Whether the anticipated reduction in orders from the largest U.S. telemedicine customer occurred, and the resulting effect on revenue, margins, and customer concentration.
- Cash burn, working capital, access to financing, and the timing and size of FC2-related SWK payments; assess the effects of the revenue-linked financing and residual royalty.
- Whether FC2 manufacturing, critical nitrile-sheath supply, shipping, and customer collections remained reliable as pandemic conditions evolved.
- Clinical-trial enrollment, site access, regulatory progress, and funding for VERU-111 and the other pipeline programs; distinguish management targets from achieved milestones.
- PPP loan forgiveness and eligibility outcome. Also note that the filing’s statement of operations reports prior-year quarterly loss per share of $0.06, while the MD&A text states $0.07; verify against the filed financial statements.